ILK and hepatocellular carcinoma: It has been found that the overexpression of kinase-inactive ILK increases the sensitivity of EGFR-resistant hepatoma cell lines to the EGFR inhibitors erlotinib, gefitinib and cetuximab in vitro and in vivo[38].